SIREN : 814046280
PHARMAFOU is a French company founded 10 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in MUSSIDAN (24400), this company of category PME shows in 2025 a net income positive of 295 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Net income | 295 298 € | 114 198 € | 115 937 € | 83 999 € | 143 341 € | 92 016 € | 86 797 € | -65 810 € |
| EBITDA | -4 236 € | -4 111 € | -3 577 € | -3 463 € | -3 566 € | -3 326 € | -7 975 € | -51 374 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
In 2025, PHARMAFOU generates positive net income of 295 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
-4 236 €
-4 236 €
295 298 €
The debt ratio (= Financial debt / Equity x 100) stands at 43%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 70%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.6 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability.
43.496%
69.688%
1.554
In 2025, the debt ratio of PHARMAFOU (43.50) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of PHARMAFOU (69.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2025, the repayment capacity of PHARMAFOU (1.55) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
-130.5
In 2025, the interest coverage of PHARMAFOU (-130.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Based on 170 transactions of similar company sales (all years), the value of PHARMAFOU is estimated at 3 061 295 € (range 1 897 558€ - 4 761 278€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMAFOU with other companies in the same sector:
Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires
The revenue of PHARMAFOU is not publicly disclosed (confidential accounts filed with INPI).
Yes, PHARMAFOU generated a net profit of 295 k€ in 2025.
The headquarters of PHARMAFOU is located in MUSSIDAN (24400), in the department Dordogne.
The tax return of PHARMAFOU is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMAFOU operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.